JAC Advance Access published online on March 31, 2004
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkh180
© 2004 by The British Society for Antimicrobial Chemotherapy
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original article
1 Department of Medical Microbiology, City Hospital NHS Trust,
Dudley Road, Birmingham B18 7QH, UK
* Corresponding author. E-mail: adam.fraise{at}swbh.nhs.uk.
Received 18 April 2003
; revised 4 February 2004
; accepted 11 February 2004
Objectives: The in vitro activity
of a new fluoroquinolone, ABT-492, was determined. Methods: MICs were compared with those of two Results: MIC data indicate that ABT-492 has
potent activity against Gram-positive organisms with enhanced anti-staphylococcal
activity compared with earlier fluoroquinolones, in addition to
activity against Conclusions: ABT-492 is a new fluoroquinolone
with excellent activity against both Gram-positive and Gram-negative
organisms, with many potential clinical uses.
Keywords: antibacterials, bacterial resistance, quinolones
Comparative study of the in vitro activity
of a new fluoroquinolone, ABT-492
-lactams, telithromycin, ciprofloxacin
and four later generation fluoroquinolones. The effects of human
serum and of inoculum concentration were also investigated.-haemolytic streptococci,
pneumococci including penicillin- and fluoroquinolone-resistant
strains and vancomycin-susceptible and -resistant Enterococcus
faecalis but not Enterococcus faecium. ABT-492
was the most active agent tested against Haemophilus
influenzae, Moraxella catarrhalis, Neisseria
meningitidis, fluoroquinolone-susceptible Neisseria
gonorrhoeae and anaerobes. Good activity was observed for
ABT-492 amongst the Enterobacteriaceae and anaerobes tested,
but ciprofloxacin showed superior activity for species of Proteus, Morganella and Providencia, as
well as for Pseudomonas spp. In common with the other
fluoroquinolones tested, organisms with reduced susceptibility to
ciprofloxacin had raised MIC90s to ABT-492. The one isolate
of H. influenzae tested with reduced fluoroquinolone
susceptibility had an ABT-492 MIC close to that of the population
lacking a mechanism of quinolone resistance. ABT-492 was more active than
ciprofloxacin against Chlamydia spp. An inoculum
effect was observed with a number of isolates of Staphylococcus
aureus, Streptococcus pneumoniae, E.
faecium, Klebsiella spp. and Escherichia
coli, in addition to moderately raised MICs in the presence
of 70% serum protein. The clinical significance of these findings
is yet to be determined.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. D. Hermsen, L. B. Hovde, K. A. Sprandel, K. A. Rodvold, and J. C. Rotschafer Levofloxacin plus Metronidazole Administered Once Daily versus Moxifloxacin Monotherapy against a Mixed Infection of Escherichia coli and Bacteroides fragilis in an In Vitro Pharmacodynamic Model Antimicrob. Agents Chemother., February 1, 2005; 49(2): 685 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Hammerschlag and P. M. Roblin The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae J. Antimicrob. Chemother., July 1, 2004; 54(1): 281 - 282. [Full Text] [PDF]
|
|